Veracyte, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the fiscal quarter ended September 30, 2026, and reporting condensed consolidated financial results for the three and nine months ended on that date.

Key Highlights

  • Total assets: Veracyte reported total assets of $1,573,256 thousand as of September 30, 2026, up from $1,406,019 thousand as of December 31, 2025.
  • Cash and cash equivalents: Cash and cash equivalents stood at $199,828 thousand as of September 30, 2026, compared with $362,578 thousand at December 31, 2025.
  • Short-term investments: Short-term investments increased to $170,704 thousand from $50,311 thousand at year-end 2025.
  • Goodwill: Goodwill rose to $855,575 thousand as of September 30, 2026, from $767,154 thousand at December 31, 2025.
  • Intangible assets, net: Net intangible assets increased to $184,883 thousand from $89,148 thousand at December 31, 2025.
  • Shares outstanding: As of October 30, 2026, there were 80,695,480 shares of common stock outstanding, par value $0.001 per share.

Veracyte's Balance Sheet Position as of September 30, 2026

According to the filing, Veracyte (NASDAQ:VCYT) reported total current assets of $467,878 thousand as of September 30, 2026, compared with $488,376 thousand at December 31, 2025. The composition shifted notably, with the company disclosing a decrease in cash and cash equivalents to $199,828 thousand from $362,578 thousand, offset in part by a rise in short-term investments to $170,704 thousand from $50,311 thousand. Accounts receivable increased to $56,788 thousand from $44,660 thousand, and supplies rose to $25,818 thousand from $20,546 thousand.

On the non-current side, the filing disclosed that goodwill expanded to $855,575 thousand from $767,154 thousand, and net intangible assets grew to $184,883 thousand from $89,148 thousand, increases the company attributed in part to its acquisition activities, including the integration of Convergent Genomics, Inc., referenced in the forward-looking statements section. Right-of-use assets for operating leases were reported at $35,097 thousand, down slightly from $36,599 thousand at year-end 2025. Property, plant and equipment, net, increased to $24,870 thousand from $22,192 thousand.

On the liabilities side, the filing reported accounts payable of $9,710 thousand as of September 30, 2026, up from $4,593 thousand at December 31, 2025, and accrued liabilities of $60,087 thousand compared with $48,801 thousand at year-end. Current deferred revenue stood at $864 thousand, down from $1,160 thousand. The company is classified as a large accelerated filer and confirmed it is not a shell company. All forward-looking statements in the filing are the company's own and are subject to its cautionary language regarding risks and uncertainties.

What Was Disclosed

Veracyte filed its Form 10-Q for the quarter ended September 30, 2026, disclosing condensed consolidated balance sheet data showing total assets of $1,573,256 thousand, a shift in liquidity from cash toward short-term investments, and higher goodwill and intangible assets compared with December 31, 2025.